MedKoo product information:

 Leuprolide Acetate

leuprolide acetate is the acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Approvals

* Lupron Injection (5 mg/mL for daily subcutaneous injection) was first approved by the FDA for treatment of advanced prostate cancer on April 9, 1985.
* Lupron Depot (7.5 mg/vial for monthly intramuscular depot injection) was first approved by the FDA for palliative treatment of advanced prostate cancer on January 26, 1989, and subsequently in 22.5 mg/vial and 30 mg/vial for intramuscular depot injection every 3 and 4 months, respectively. 3.75 mg/vial and 11.25 mg/vial dosage forms were subsequently approved for subcutaneous depot injection every month and every 3 months, respectively for treatment of endometriosis or fibroids. 7.5 mg/vial, 11.25 mg/vial, and 15 mg/vial dosage forms were subsequently approved for subcutaneous depot injection for treatment of children with central precocious puberty.
* Viadur (72 mg yearly subcutaneous implant) was first approved by the FDA for palliative treatment of advanced prostate cancer on March 6, 2000.
* Eligard (7.5 mg for monthly subcutaneous depot injection) was first approved by the FDA for palliative treatment of advanced prostate cancer on January 24, 2002, and subsequently in 22.5 mg, 30 mg, and 45 mg doses for subcutaneous depot injection every 3, 4, and 6 months, respectively.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals (1985-2008) and Abbott Laboratories (2008-current) under the brand name Lupron. It is available as a slow-release implant or subcutaneous/intramuscular injection. In the UK and Ireland , leuprorelin is marketed by Takeda UKProstap SR(one month injection) and Prostap 3 (three month injection). The above information was directly from: http://en.wikipedia.org/wiki/Leuprolide_acetate.

DRUG DESCRIPTION

ELIGARD® is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver leuprolide acetate at a controlled rate over a one-, three-, four- or six-month therapeutic period. Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH) that, when given continuously, inhibits pituitary gonadotropin secretion and suppresses testicular and ovarian steroidogenesis. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L- histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt).  ELIGARD® is prefilled and supplied in two separate, sterile syringes whose contents are mixed immediately prior to administration. The two syringes are joined and the single dose product is mixed until it is homogenous. ELIGARD® is administered subcutaneously, where it forms a solid drug delivery depot. One syringe contains the ATRIGEL® Delivery System and the other contains leuprolide acetate. ATRIGEL® is a polymeric (non-gelatin containing) delivery system consisting of a biodegradable poly (DL-lactide-co-glycolide) (PLGH or PLG) polymer formulation dissolved in a biocompatible solvent, N-methyl-2-pyrrolidone (NMP).

CLINICAL PHARMACOLOGY

Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy. In humans, administration of leuprolide acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in premenopausal females). However, continuous administration of leuprolide acetate results in decreased levels of LH and FSH. In males, testosterone is reduced to below castrate threshold ( ≤ 50 ng/dL). These decreases occur within two to four weeks after initiation of treatment. Long-term studies have shown that continuation of therapy with leuprolide acetate maintains testosterone below the castrate level for up to seven years.

 1: Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C, Germa JR. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. Clin Ther. 2010 Apr;32(4):744-57. PubMed PMID: 20435244.

2: Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010 Jun 1;28(16):2668-73. Epub 2010 Apr 26. PubMed PMID: 20421544.

3: Park HJ, Koo YA, Im YH, Yoon BK, Choi D. GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients. J Korean Med Sci. 2010 Jan;25(1):110-6. Epub 2009 Dec 26. PubMed PMID: 20054409; PubMed Central PMCID: PMC2800030.

4: Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics. Eur Urol. 2009 Nov 20. [Epub ahead of print] PubMed PMID: 19962227.

5: Boccon-Gibod L, Iversen P, Persson BE. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer. Expert Rev Anticancer Ther. 2009 Dec;9(12):1737-43. PubMed PMID: 19954284.

6: Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2009 Nov 13. [Epub ahead of print] PubMed PMID: 19912212.

7: Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009 Oct 1;69(14):1967-76. doi: 10.2165/10484080-000000000-00000. PubMed PMID: 19747011.

8: Matousek RH, Sherwin BB. A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology. 2010 Feb;35(2):215-25. Epub 2009 Jul 16. PubMed PMID: 19615826.

9: Persson BE, Kold Olesen T, Jensen JK. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 2009;90(3):235-44. Epub 2009 Jul 14. PubMed PMID: 19602868.

10: Wang PH, Lee WL, Cheng MH, Yen MS, Chao KC, Chao HT. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas. Taiwan J Obstet Gynecol. 2009 Jun;48(2):133-7. PubMed PMID: 19574174.

11: Doehn C, Sommerauer M, Jocham D. Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Interv Aging. 2009;4:215-23. Epub 2009 May 14. Review. PubMed PMID: 19503784; PubMed Central PMCID: PMC2685243.

12: Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol. 2009 May;5(4):433-43. Review. PubMed PMID: 19450172.

13: Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. Epub . PubMed PMID: 19395192.

14: Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. Epub 2009 Mar 14. PubMed PMID: 19289266.

15: Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 2009 Sep;104(6):806-12. Epub 2009 Mar 5. PubMed PMID: 19281463.

16: Moul JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 2009 Jan;103(2):145-6. PubMed PMID: 19278531.

17: Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009 Mar;181(3):1104-13; discussion 1113. Epub 2009 Jan 23. PubMed PMID: 19167733; PubMed Central PMCID: PMC2838198.

18: Maisano R, Caristi N, Mare M, Bottari M, Adamo V, Mafodda A, Calogero MG, Caruso M, Nardi M. Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study. J Chemother. 2008 Dec;20(6):740-3. PubMed PMID: 19129073.

19: Greil S, Robinson EA, Singal B, Kleer E. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals. Urology. 2009 Mar;73(3):631-4. Epub 2008 Dec 24. PubMed PMID: 19110301.

20: Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology. 2009 Mar;73(3):635-40. Epub 2008 Nov 26. PubMed PMID: 19038426.

21: Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. PubMed PMID: 19035858.

22: Tunn UW, Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis. 2009;12(1):83-7. Epub 2008 Nov 25. PubMed PMID: 19030021.

23: Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E; Cancer Leukemia Group B. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 1;113(11):3137-45. PubMed PMID: 18989865.

24: Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009 Feb;94(2):469-76. Epub 2008 Nov 4. PubMed PMID: 18984667; PubMed Central PMCID: PMC2646515.

25: Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists. Fertil Steril. 2009 Apr;91(4 Suppl):1574-7. Epub 2008 Oct 29. PubMed PMID: 18973892.

26: Wang PH, Liu WM, Fuh JL, Cheng MH, Chao HT. Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril. 2009 Sep;92(3):876-85. Epub 2008 Sep 6. PubMed PMID: 18774566.

27: Bhatia K, Doonan Y, Giannakou A, Bentick B. A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium. BJOG. 2008 Sep;115(10):1214-24. Erratum in: BJOG. 2008 Dec;115(13):1723. PubMed PMID: 18715405.

28: Okuda S, Oshio K, Shinmoto H, Tanimoto A, Asada H, Fujii T, Yoshimura Y, Kuribayashi S. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience. Radiology. 2008 Sep;248(3):917-24. PubMed PMID: 18710984.

29: Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008 Oct;180(4):1432-7; discussion 1437. Epub 2008 Aug 16. PubMed PMID: 18710748; PubMed Central PMCID: PMC2564996.

30: Soga N, Arima K, Sugimura Y. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade. Jpn J Clin Oncol. 2008 Sep;38(9):617-22. Epub 2008 Aug 12. PubMed PMID: 18697759.

31: D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008 Jun 20;26(18):2979-83. PubMed PMID: 18565884.

32: Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-65. PubMed PMID: 18565882.

33: Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer. 2008 Mar;6(1):46-52. PubMed PMID: 18501083.

34: Coddington CC, Grow DR, Ahmed MS, Toner JP, Cook E, Diamond MP. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. Fertil Steril. 2009 May;91(5):1909-13. Epub 2008 Apr 25. PubMed PMID: 18439584.

35: Yassa M, Fortin B, Fortin MA, Lambert C, Van Nguyen T, Bahary JP. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):58-63. PubMed PMID: 18406883.

36: Petit JH, Gluck C, Kiger WS 3rd, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol. 2008 Jul-Aug;26(4):372-7. Epub 2008 Jan 8. PubMed PMID: 18367113.

37: Lim SS, Sockalingam JK, Tan PC. Goserelin versus leuprolide before hysterectomy for uterine fibroids. Int J Gynaecol Obstet. 2008 May;101(2):178-83. Epub 2007 Dec 31. PubMed PMID: 18164303.

38: Palomba S, Orio F Jr, Falbo A, Oppedisano R, Tolino A, Zullo F. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. Fertil Steril. 2008 Jul;90(1):165-73. Epub 2007 Nov 14. PubMed PMID: 18001721.

39: Kundranda MN, Muslimani A, Daw HA, Spiro TP. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin Genitourin Cancer. 2007 Sep;5(6):401-2. PubMed PMID: 17956714.

40: Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005287. Review. PubMed PMID: 17943846.

41: Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol. 2008 Aug;62(3):373-7. Epub 2007 Oct 9. PubMed PMID: 17922273.

42: Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007 Jun 20;25(18):2509-15. PubMed PMID: 17577027.

43: Pathak AS, Pacificar JS, Shapiro CE, Williams SG. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol. 2007 Jun;177(6):2132-5; discussion 2135. PubMed PMID: 17509298.

44: Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):3-8. Epub 2007 Apr 27. Review. PubMed PMID: 17467142.

45: Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008 Jan;89(1):84-91. Epub 2007 Apr 26. PubMed PMID: 17462639.

46: Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology. 2008 Feb;17(2):148-53. PubMed PMID: 17443645.

47: Lingxia X, Taixiang W, Xiaoyan C. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005287. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD005287. PubMed PMID: 17443581.

48: Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):516-25. PubMed PMID: 17405996.

49: Raina R, Pahalajani G, Agarwal A, Zippe C. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian J Androl. 2007 Mar;9(2):253-8. PubMed PMID: 17334592.

50: Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007 Mar 1;109(5):858-67. PubMed PMID: 17265527.

51: D'Amico A. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU Int. 2007 Jan;99 Suppl 1:13-6; discussion 17-8. Review. PubMed PMID: 17229162.

52: Akaza H. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer. BJU Int. 2007 Jan;99 Suppl 1:10-2; discussion 17-8. Review. PubMed PMID: 17229161.

53: Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective. BJU Int. 2007 Jan;99 Suppl 1:6-9; discussion 17-8. Review. PubMed PMID: 17229160.

54: Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int. 2007 Jan;99(1):60-7. PubMed PMID: 17227493.

55: Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007;10(2):194-201. Epub 2007 Jan 2. PubMed PMID: 17199134.

56: Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, Schiff PB, Mansukhani MM, Ennis RD. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007 Jan 1;25(1):77-84. PubMed PMID: 17194907.

57: Uray IP, Brown PH. Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec;15(12):1583-600. Review. PubMed PMID: 17107283.

58: Coli S, Magnoni M, Melisurgo G, Persico P, Doldi N, De Cobelli F, Del Maschio A, Cianflone D, Maseri A. Myocardial infarction complicating the initial phase of an ovarian stimulation protocol. Int J Cardiol. 2007 Jan 31;115(1):e56-7. Epub 2006 Oct 24. PubMed PMID: 17067704.

59: Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer]. Nippon Hinyokika Gakkai Zasshi. 2006 Jul;97(5):712-8. Japanese. PubMed PMID: 16898594.

60: Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review. PubMed PMID: 16787142.

61: Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer. 2006 Jul 15;107(2):389-95. PubMed PMID: 16783817.

62: De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig. 2006 May;13(4):297-303. PubMed PMID: 16697947.

63: Taguchi T, Noguchi S. [Clinical applications of GnRHa in breast cancer]. Nippon Rinsho. 2006 Apr;64 Suppl 4:85-9. Review. Japanese. PubMed PMID: 16689290.

64: Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res. 2006 Mar-Apr;26(2B):1583-7. PubMed PMID: 16619575.

65: Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006 Feb;175(2):533-6. PubMed PMID: 16406989.

66: Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7. Review. PubMed PMID: 16375643.

67: Morgan G, Cooley C. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions. Eur J Oncol Nurs. 2005 Dec;9(4):334-40. Epub 2005 Nov 17. PubMed PMID: 16298160.

68: Pickles T. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol. 2005 Dec;174(6):2423-4; author reply 2424. PubMed PMID: 16280866.

69: Pollack A, Horwitz EM. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer? Nat Clin Pract Oncol. 2005 Jan;2(1):12-3. PubMed PMID: 16264846.

70: Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int. 2005;75(3):204-8. PubMed PMID: 16215305.

71: Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Rev Anticancer Ther. 2005 Aug;5(4):605-11. Review. PubMed PMID: 16111462.

72: Malone S, Perry G, Segal R, Dahrouge S, Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int. 2005 Sep;96(4):514-20. PubMed PMID: 16104902.

73: Zhou YF, Yang DZ, Hu LN, Zheng SR. [Clinical trial on the effectiveness and safety of triptorelin in treatment of uterine leiomyoma]. Zhonghua Fu Chan Ke Za Zhi. 2005 Jul;40(7):460-3. Chinese. PubMed PMID: 16080872.

74: Miyake H, Hara I, Yamazaki H, Eto H. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep. 2005 Sep;14(3):673-6. PubMed PMID: 16077973.

75: De Falco M, Staibano S, Pollio F, Salvatore G, Pontillo M, Ciociola F, Mansueto G, Di Lieto A. Expression of proliferating cell nuclear antigen and bcl-2 during a pseudomenopausal state induced by presurgical treatment of uterine leiomyomas with gonadotropin-releasing hormone analogues plus tibolone. Int J Gynecol Pathol. 2005 Jul;24(3):286-91. PubMed PMID: 15968206.

76: Appu S, Lawrentschuk N, Grills RJ, Neerhut G. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer. J Urol. 2005 Jul;174(1):140-2. PubMed PMID: 15947599.

77: Lethaby A, Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Am Fam Physician. 2005 May 1;71(9):1753-6. Review. PubMed PMID: 15887454.

78: Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, Guo C. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol. 2005 Apr 20;23(12):2789-96. PubMed PMID: 15837994.

79: Mizutani T, Sugihara A, Honma H, Komura H, Nakamuro K, Terada N. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Gynecol Endocrinol. 2005 Feb;20(2):80-3. PubMed PMID: 15823826.

80: Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol. 2005 May;173(5):1567-71. Erratum in: J Urol. 2005 Aug;174(2):796. Sartor, Oliver [added]; Higano, Celestia S [added]; Petrylak, Daniel P [added] Chatta, Gerkamal [added]. PubMed PMID: 15821487.

81: Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. Drugs R D. 2005;6(1):53-5. Review. PubMed PMID: 15801868.

82: Bahçeci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med. 2005 Feb;50(2):84-90. PubMed PMID: 15755044.

83: Rao GG, Miller DS. Clinical applications of hormonal therapy in ovarian cancer. Curr Treat Options Oncol. 2005 Mar;6(2):97-102. Review. PubMed PMID: 15717991.

84: Montgomery BS, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection. Prostate Cancer Prostatic Dis. 2005;8(1):66-8. PubMed PMID: 15700050.

85: Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G, Staibano S. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005 Feb;12(2):123-8. PubMed PMID: 15695108.

86: Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril. 2005 Jan;83(1):1-23. Review. PubMed PMID: 15652881.

87: Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology. 2004 Dec;40(6):1361-9. PubMed PMID: 15565568.

88: Sokoloff MH, Rinker-Schaeffer CW, Chung LW, Brendler CB. Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells. J Urol. 2004 Dec;172(6 Pt 2):2539-44. Review. PubMed PMID: 15538203.

89: Yamanaka H, Ito K, Naito S, Tsukamoto T, Usami M, Fujimoto H, Matsuoka N, Fukui I, Harada M, Ohashi Y, Kotake T, Kakizoe T. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate. 2005 Apr 1;63(1):56-64. PubMed PMID: 15468166.

90: Balbi G, Piano LD, Cardone A, Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):799-803. PubMed PMID: 15361187.

91: Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment Group. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 1;101(5):969-72. PubMed PMID: 15329905.

92: D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18;292(7):821-7. PubMed PMID: 15315996.

93: Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M; Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology. 2004 Aug;64(2):341-5. PubMed PMID: 15302491.

94: Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate. 2004 Sep 1;60(4):310-6. PubMed PMID: 15264242.

95: Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 1;22(13):2546-53. PubMed PMID: 15226323.

96: Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004 Sep;29(8):1071-81. PubMed PMID: 15219659.

97: Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Int J Urol. 2004 May;11(5):295-303. PubMed PMID: 15147545.

98: Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004 May;93(7):975-9. PubMed PMID: 15142146.

99: Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Doldo P, Nappi C, Lombardi G, Mastrantonio P, Zullo F. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod. 2004 Jun;19(6):1308-14. Epub 2004 Apr 29. PubMed PMID: 15117890.

100: Prezioso D, Lotti T, Polito M, Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004;72(3):189-95. PubMed PMID: 15084760.

101: Stock RG, Stone NN. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy. 2002;1(1):2-10. Review. PubMed PMID: 15062181.

102: Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9. PubMed PMID: 15050332.

103: Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. Int J Urol. 2004 Apr;11(4):218-24. PubMed PMID: 15028100.

104: Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004 Jan;34(1):20-8. PubMed PMID: 15020659.

105: Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2004 Feb;5(2):447-57. Review. PubMed PMID: 14996640.

106: Palomba S, Russo T, Orio F Jr, Sammartino A, Sbano FM, Nappi C, Colao A, Mastrantonio P, Lombardi G, Zullo F. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod. 2004 Feb;19(2):415-21. PubMed PMID: 14747190.

107: Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology. 2003 Dec 22;62(6 Suppl 1):36-42. Review. PubMed PMID: 14706507.

108: Moul JW, Fowler JE Jr. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. Urology. 2003 Dec 22;62(6 Suppl 1):20-8. PubMed PMID: 14706505.

109: Carr BR, Breslau NA, Peng N, Adams-Huet B, Bradshaw KD, Steinkampf MP. Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial. Fertil Steril. 2003 Nov;80(5):1216-23. PubMed PMID: 14607578.

110: Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003 Nov;170(5):1808-11. PubMed PMID: 14532781.

111: Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K; Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group. Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Res Treat. 2003 Aug;80(3):245-55. PubMed PMID: 14503797.

112: Di Lieto A, De Falco M, Staibano S, Iannotti F, Scaramellino M, Salvatore G, Mansueto G, Granata P, Pontillo M, Pollio F, De Rosa G. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol. 2003 Oct;22(4):353-8. PubMed PMID: 14501815.

113: Wachter S, Wachter-Gerstner N, Pötter R. Neoadjuvant hormonal treatment and radiotherapy for prostate cancer. Oncology. 2003;65 Suppl 1:29-33. Review. PubMed PMID: 12949431.

114: Douchi T, Kuwahata T, Yoshimitsu N, Iwamoto I, Yamasaki H, Nagata Y. Changes in serum leptin levels during GnRH agonist therapy. Endocr J. 2003 Jun;50(3):355-9. PubMed PMID: 12940465.

115: Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. 2003 Aug;62(2):319-23. PubMed PMID: 12893343.

116: Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC; South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003 Aug;92(3):226-31. PubMed PMID: 12887472.

117: Oh WK. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-Jun;21(3):229-34. Review. PubMed PMID: 12810211.

118: Williams G, Lindsay S, Bowsher WG. Randomised crossover trial to assess the tolerability of LHRH analogue administration. Prostate Cancer Prostatic Dis. 2003;6(2):187-9. PubMed PMID: 12806381.

119: Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. Am J Clin Oncol. 2003 Jun;26(3):312-6. PubMed PMID: 12796607.

120: Dockery F, Bulpitt CJ, Agarwal S, Rajkumar C. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male. 2002 Dec;5(4):216-22. PubMed PMID: 12630068.

121: Koiso K, Akaza H, Naito S, Usami M, Tsukamoto T, Shimazaki J, Kotake T, Yamanaka H, Oohashi Y, Yoshinaka R, Onouchi H, Yokokawa K. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. Hinyokika Kiyo. 2002 Dec;48(12):781-95. Japanese. PubMed PMID: 12613016.

122: Koiso K, Yamanaka H, Ito K, Yoshinaka R, Uchida S, Yokokawa K. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. Hinyokika Kiyo. 2002 Dec;48(12):771-9. Japanese. PubMed PMID: 12613015.

123: Namiki M, Mizokami A. [Total androgen blockade]. Nippon Rinsho. 2002 Dec;60 Suppl 11:193-8. Review. Japanese. PubMed PMID: 12599570.

124: Miyanaga N, Akaza H. [Characteristics, effects, side effects of the LH-RH agonist]. Nippon Rinsho. 2002 Dec;60 Suppl 11:177-81. Review. Japanese. PubMed PMID: 12599567.

125: Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002 Nov;24(11):1902-14. PubMed PMID: 12501882.

126: Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. 1999 Jan;2(1):4-8. PubMed PMID: 12496859.

127: Gommersall LM, Hayne D, Shergill IS, Arya M, Wallace DM. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer. Expert Opin Pharmacother. 2002 Dec;3(12):1685-92. Review. PubMed PMID: 12472366.

128: Palomba S, Russo T, Orio F Jr, Tauchmanovà L, Zupi E, Panici PL, Nappi C, Colao A, Lombardi G, Zullo F. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002 Dec;17(12):3213-9. PubMed PMID: 12456626.

129: Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization. Reprod Biomed Online. 2002 Sep-Oct;5(2):112-6. PubMed PMID: 12419034.

130: Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Nappi C, Mastrantonio P, Lombardi G, Colao A, Zullo F. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab. 2002 Oct;87(10):4476-81. PubMed PMID: 12364422.

131: Hara I, Miyake H, Yamada Y, Takechi Y, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Soejima T, Sugimura K, Kamidono S. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol. 2002 Jun;9(6):322-8; discussion 328. PubMed PMID: 12269247.

132: Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology. 2002 Sep-Oct;11(5):401-14. PubMed PMID: 12228873.

133: Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002 Sep;168(3):1199-203. PubMed PMID: 12187267.

134: Sharifi R, Browneller R; Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002 Sep;168(3):1001-4. PubMed PMID: 12187208.

135: Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002 Sep;90(4):427-32. PubMed PMID: 12175403.

136: Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res. 2002 Jul-Aug;22(4):2325-32. PubMed PMID: 12174922.

137: Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology. 2002 Jul;60(1):115-9. PubMed PMID: 12100935.

138: Palomba S, Morelli M, Di Carlo C, Noia R, Pellicano M, Zullo F. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone. Fertil Steril. 2002 Jul;78(1):63-8. PubMed PMID: 12095492.

139: Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485-504. Review. PubMed PMID: 12083977.

140: Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr;167(4):1670-4. PubMed PMID: 11912385.

141: du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol. 2002 Feb;13(2):251-7. PubMed PMID: 11886002.

142: Parker CC, Norman AR, Huddart RA, Horwich A, Dearnaley DP. Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer. 2002 Mar 4;86(5):686-91. PubMed PMID: 11875726; PubMed Central PMCID: PMC2375313.

143: Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. PubMed PMID: 11836291.

144: Saito S, Nakashima J, Nakajima Y, Ikeuchi K, Shibayama T, Nagakura K, Naide Y, Hayakawa M, Ogawa Y, Hata M, Nakazono M, Hasegawa S, Oda T, Kimura S, Nakamura S, Matsunaga J, Fujioka T, Tanoguchi H, Aoki S, Yamamoto Y, Izawa A, Kimura S, Suzuki K, Tazaki H, Murai M; Keio University Prostate Cancer Study Group. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer]. Nippon Hinyokika Gakkai Zasshi. 2001 Nov;92(7):682-93. Japanese. PubMed PMID: 11766367.

145: Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002 Jan;167(1):112-6. PubMed PMID: 11743286.

146: Leuprorelin and triptorelin: new indication. Preoperative treatment of uterine leiomyoma: no proven value. Prescrire Int. 2001 Jun;10(53):73-7. PubMed PMID: 11718167.

147: McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001 Nov;58(5):756-61. PubMed PMID: 11711355.

148: Noguchi K, Uemura H, Harada M, Miura T, Moriyama M, Fukuoka H, Kitami K, Hosaka M. Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist. Int J Clin Oncol. 2001 Feb;6(1):29-33. PubMed PMID: 11706524.

149: Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1117-20. PubMed PMID: 11700258.

150: Lhommé C, Brault P, Bourhis JH, Pautier P, Dohollou N, Dietrich PY, Akbar-Zadeh G, Lucas C, Pico JL, Hayat M. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma. 2001 Sep-Oct;42(5):1033-41. PubMed PMID: 11697620.

151: Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Semin Oncol. 2001 Aug;28(4 Suppl 15):22-31. PubMed PMID: 11685725.

152: Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):605-13. PubMed PMID: 11597799.

153: Abulafia O, Kleinhaus K, Levi G, Lee YC, Sherer DM. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma. Gynecol Obstet Invest. 2001;52(2):108-13. PubMed PMID: 11586038.

154: Jasonni VM, D'Anna R, Mancuso A, Caruso C, Corrado F, Leonardi I. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. Acta Obstet Gynecol Scand. 2001 Oct;80(10):956-8. PubMed PMID: 11580742.

155: Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27;345(13):948-55. PubMed PMID: 11575286.

156: Fowler JE Jr; Viadur Study Group. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology. 2001 Sep;58(3):430-4. PubMed PMID: 11549494.

157: Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology. 2001 Aug;58(2 Suppl 1):24-7. PubMed PMID: 11502441.

158: Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001 Aug;166(2):500-6; discussion 506-7. PubMed PMID: 11458055.

159: Somekawa Y, Chiguchi M, Ishibashi T, Wakana K, Aso T. Efficacy of ipriflavone in preventing adverse effects of leuprolide. J Clin Endocrinol Metab. 2001 Jul;86(7):3202-6. PubMed PMID: 11443189.

160: Collette L, Studer UE, Schröder FH, Denis LJ, Sylvester RJ. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate. 2001 Jun 15;48(1):29-39. PubMed PMID: 11391684.

161: Pereyra Pacheco B, Méndez Ribas JM, Milone G, Fernández I, Kvicala R, Mila T, Di Noto A, Contreras Ortiz O, Pavlovsky S. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001 Jun;81(3):391-7. PubMed PMID: 11371127.

162: Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001 May;165(5):1585-9. PubMed PMID: 11342922.

163: Tsushima T, Nasu Y, Saika T, Maki Y, Noda M, Suyama B, Yamato T, Kumon H. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int. 2001;66(3):135-9. PubMed PMID: 11316974.

164: Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist. 2001;6(2):177-82. PubMed PMID: 11306729.

165: Nakazato H, Suzuki K, Ito K, Fukabori Y, Kurokawa K, Yamanaka H. [Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients]. Nippon Hinyokika Gakkai Zasshi. 2001 Jan;92(1):6-12. Japanese. PubMed PMID: 11235144.

166: Palomba S, Pellicano M, Affinito P, Di Carlo C, Zullo F, Nappi C. Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil Steril. 2001 Feb;75(2):429-33. PubMed PMID: 11172852.

167: Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2001 Feb;86(2):511-6. PubMed PMID: 11158001.

168: Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res. 2000 Oct;26(5):325-31. PubMed PMID: 11147718.

169: Muneyyirci-Delale O, Weisberg GW. Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? Int J Fertil Womens Med. 2000 Nov-Dec;45(6):368-71. PubMed PMID: 11140546.

170: Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review. PubMed PMID: 11098244.

171: Muenstermann U, Kleinstein J. Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. Hum Reprod. 2000 Dec;15(12):2526-30. PubMed PMID: 11098021.

172: Klotz L, Gleave M, Goldenberg SL. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol. 2000 Fall;4(3):233-7;discussion 239. Review. PubMed PMID: 11062379.

173: Sano M, Makino H. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer]. Nippon Rinsho. 2000 Apr;58 Suppl:328-33. Review. Japanese. PubMed PMID: 11026014.

174: Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients. Hinyokika Kiyo. 2000 Aug;46(8):531-6. PubMed PMID: 11019371.

175: Scialli AR, Levi AJ. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril. 2000 Sep;74(3):540-6. PubMed PMID: 10973652.

176: Fowler JE Jr, Gottesman JE, Reid CF, Andriole GL Jr, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol. 2000 Sep;164(3 Pt 1):730-4. PubMed PMID: 10953135.

177: Stone NN, Stock RG. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer. Mol Urol. 1999;3(3):239-244. PubMed PMID: 10851329.

178: Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group. Jpn J Clin Oncol. 2000 Mar;30(3):131-6. PubMed PMID: 10798540.

179: Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology. 2000 May;55(5):639-42. PubMed PMID: 10792069.

180: Leuprorelin implant (ALZA). DUROS, leuprolide acetate implant, leuprolide implant, Viadur. Drugs R D. 1999 Dec;2(6):425-6. PubMed PMID: 10763458.

181: Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5. PubMed PMID: 10744594.

182: Weeks AD, Duffy SR, Walker JJ. A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. BJOG. 2000 Mar;107(3):323-8. PubMed PMID: 10740327.

183: Verspyck E, Marpeau L, Lucas C. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. Eur J Obstet Gynecol Reprod Biol. 2000 Mar;89(1):7-13. PubMed PMID: 10733017.

184: Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab. 2000 Mar;85(3):995-1000. PubMed PMID: 10720029.

185: Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology. 2000 Mar;55(3):391-5; discussion 395-6. PubMed PMID: 10699617.

186: Hussain M, Fisher EI, Petrylak DP, O'Connor J, Wood DP, Small EJ, Eisenberger MA, Crawford ED. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. J Clin Oncol. 2000 Mar;18(5):1043-9. PubMed PMID: 10694555.

187: Nakayama H, Yano T, Sagara Y, Kikuchi A, Ando K, Wang Y, Watanabe M, Matsumi H, Osuga Y, Momoeda M, Taketani Y. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Gynecol Endocrinol. 1999 Dec;13(6):382-9. PubMed PMID: 10685331.

188: Jett EA, Lerner MR, Lightfoot SA, Hanas JS, Brackett DJ, Hollingsworth AB. Prevention of rat mammary carcinoma utilizing leuprolide as an equivalent to oophorectomy. Breast Cancer Res Treat. 1999 Nov;58(2):131-6. PubMed PMID: 10674877.

189: van der Kwast TH, Labrie F, Tetu B. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum Pathol. 1999 Dec;30(12):1503-7. PubMed PMID: 10667430.

190: Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology. 2000 Jan;55(1):97-101. PubMed PMID: 10654902.

191: Hutchins FL, Worthington-Kirsch R, Berkowitz RP. GnRH analogs and uterine artery embolization. J Am Assoc Gynecol Laparosc. 1999 Aug;6(3):367-8. Erratum in: J Am Assoc Gynecol Laparosc 1999 Nov;6(4):523. PubMed PMID: 10610208.

192: Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fertil Steril. 1999 Nov;72(5):889-95. PubMed PMID: 10560995.

193: Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology. 1999 Oct;54(4):694-9. PubMed PMID: 10510930.

194: Sarno M, Powell H, Tjersland G, Schoendorfer D, Harris H, Adams K, Ogata P, Warnick GR. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links. Clin Chem. 1999 Sep;45(9):1501-9. PubMed PMID: 10471653.

195: Balaji KC, Rabbani F, Tsai H, Bastar A, Fair WR. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J Urol. 1999 Sep;162(3 Pt 1):753-7. PubMed PMID: 10458359.

196: Sumiyoshi Y, Hashine K, Kuwahara M, Aki M, Yamamoto A, Akazawa S, Takenaka A. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. Gan To Kagaku Ryoho. 1999 Jul;26(8):1153-8. Japanese. PubMed PMID: 10431581.

197: McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, Venner PM, Patterson AL, Sarosdy MF, Kelley RP, Kolvenbag GJ. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate. 1999 Sep 1;40(4):218-24. PubMed PMID: 10420149.

198: Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Int J Urol. 1999 May;6(5):229-37; discussion 238-9. PubMed PMID: 10375185.

199: Sica S, Salutari P, Chiusolo P, Cicconi S, Sorá F, Laurenti L, Piccirillo N, Scirpa P, Leone G. Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease. Blood. 1999 May 1;93(9):3154. PubMed PMID: 10336272.

200: Boccardo F, Rubagotti A, Amoroso D, Agostara B, Amadori D, Gallo L, Iacobelli S, Massidda B, Mesiti M, Pacini P, Tomao S, Paganuzzi M, Marroni P. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol. 1999;43(6):461-6. PubMed PMID: 10321505.

201: Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology. 1999 May;53(5):898-902; discussion 902-3. PubMed PMID: 10223480.

202: Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology. 1999 Apr;53(4):696-700. PubMed PMID: 10197843.

203: Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology. 1999 Mar;53(3):530-4. PubMed PMID: 10096379.

204: van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999 Mar;53(3):523-9. PubMed PMID: 10096378.

205: Prezioso D, Lotti T, Montironi R, Polito M. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group. Eur Urol. 1999;35 Suppl 1:17-21; discussion 22. PubMed PMID: 10081698.

206: Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K, Lobo RA. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome. Fertil Steril. 1999 Mar;71(3):439-44. PubMed PMID: 10065779.

207: Russo P, Ciolli P, Atlante M, Carico E, Mancini R, Russo R, Vecchione A. [Clinical use of leuprolide acetate depot in a group of gynecologic patients in the preoperative period]. Minerva Ginecol. 1998 Nov;50(11):499-502. Italian. PubMed PMID: 9882992.

208: Wajsman Z. Arguments for the long-term use of combined androgen blockade. Eur Urol. 1998;34 Suppl 3:25-8. Review. PubMed PMID: 9854192.

209: Gregoriou O, Vitoratos N, Konidaris S, Papadias C, Chryssikopoulos A. Evaluation of ovarian cysts following GnRH-a treatment in patients with polycystic ovarian syndrome. Gynecol Obstet Invest. 1998;46(4):252-5. PubMed PMID: 9813444.

210: Battaglia C, Genazzani AD, Artini PG, Salvatori M, Giulini S, Volpe A. Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome. Ultrasound Obstet Gynecol. 1998 Sep;12(3):180-7. PubMed PMID: 9793190.

211: Zullo F, Pellicano M, Di Carlo C, De Stefano R, Marconi D, Zupi E. Ultrasonographic prediction of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 1998 Nov;5(4):361-6. PubMed PMID: 9782139.

212: Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42. PubMed PMID: 9761805.

213: Shimada M, Uchida H, Kasahara T, Fuji K, Ogawa Y, Yoshida H, Hamajima T, Matsuda N, Ikeuchi T, Kai Y, Hiramori M, Hoshino M, Inoue K, Higaki Y. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism]. Hinyokika Kiyo. 1998 Jul;44(7):525-32. Japanese. PubMed PMID: 9752613.

214: Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety. 1998;7(4):171-7. Review. PubMed PMID: 9706454.

215: Sarosdy MF, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Klein EA, Schellenger JJ, Kolvenbag GJ. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology. 1998 Jul;52(1):82-8. PubMed PMID: 9671875.

216: Palomba S, Affinito P, Tommaselli GA, Nappi C. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril. 1998 Jul;70(1):111-8. PubMed PMID: 9660431.

217: Untch M. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group]. Zentralbl Gynakol. 1998;120(6):284-92. German. PubMed PMID: 9659699.

218: Garzetti GG, Ciavattini A, Tiriduzzi M. Combined ultrasonographically guided drainage and laparoscopic excision of large endometriomas: a pilot study. Gynecol Obstet Invest. 1998;45(4):266-8. PubMed PMID: 9623794.

219: Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology. 1998 May;51(5):782-7. PubMed PMID: 9610592.

220: Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int. 1998;60 Suppl 2:18-24; discussion 35. PubMed PMID: 9607554.

221: Prezioso D, Lotti T, Montironi R, Polito M. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group. Urol Int. 1998;60 Suppl 2:11-7; discussion 35. PubMed PMID: 9607553.

222: Guido M, Pavone V, Ciampelli M, Murgia F, Fulghesu AM, Apa R, Caruso A, Mancuso S, Lanzone A. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998 May;83(5):1742-5. PubMed PMID: 9589685.

223: Bono AV, DiSilverio F, Robustelli della Cuna G, Benvenuti C, Brausi M, Ferrari P, Gibba A, Galli L. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group. Urol Int. 1998;60 Suppl 1:18-24. PubMed PMID: 9563140.

224: Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int. 1998;60 Suppl 1:9-16; discussion 16-7. PubMed PMID: 9563139.

225: Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int. 1998;60(1):33-40. PubMed PMID: 9519419.

226: Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 1998 Feb;51(2):271-6. PubMed PMID: 9495710.

227: Abbou CC, Lucas C, Leblanc V. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer]. Prog Urol. 1997 Dec;7(6):984-95. French. PubMed PMID: 9490144.

228: Guinan P, Didomenico D, Brown J, Shaw M, Sharifi R, Ray V, Shott S, Rubenstein M. The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol. 1997 Sep-Dec;14(3-4):145-52. PubMed PMID: 9468037.

229: Zullo F, Pellicano M, De Stefano R, Zupi E, Mastrantonio P. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):108-12. PubMed PMID: 9465812.

230: Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997 Dec;82(12):4075-9. PubMed PMID: 9398716.

231: Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology. 1997 Sep;50(3):330-6. PubMed PMID: 9301693.

232: Kitahara S, Yoshida K, Ishizaka K, Kageyama Y, Kawakami S, Tsujii T, Oshima H. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J. 1997 Aug;44(4):527-32. PubMed PMID: 9447285.

233: Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer. 1997 May 15;79(10):1964-8. PubMed PMID: 9149024.

234: Lee F, Siders DB, McHug TA, Solomon MH, Klamerus ML. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Res. 1997 May-Jun;17(3A):1507-10. PubMed PMID: 9179187.

235: Zerbib M, Lucas C, Leblanc V. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study]. Prog Urol. 1997 Apr;7(2):246-53. French. PubMed PMID: 9264767.

236: Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol. 1997 Apr;15(4):1470-7. PubMed PMID: 9193342.

237: Smith JA Jr, Lange PH, Janknegt RA, Abbou CC, deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol. 1997 Apr;157(4):1329-34. PubMed PMID: 9120932.

238: Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y. Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group. Int J Urol. 1997 Mar;4(2):144-51. Erratum in: Int J Urol 1998 Nov;5(6):618. PubMed PMID: 9179687.

239: McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. Urology. 1997 Mar;49(3A Suppl):70-3. PubMed PMID: 9123740.

240: Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997 Mar;49(3A Suppl):38-45. PubMed PMID: 9123735.

241: Genazzani AD, Petraglia F, Battaglia C, Gamba O, Volpe A, Genazzani AR. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil Steril. 1997 Mar;67(3):463-8. PubMed PMID: 9091331.

242: Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb;82(2):524-30. PubMed PMID: 9024248.

243: Laverdière J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):247-52. PubMed PMID: 9069293.

244: Stolz W, Pfützenreuter N. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group]. Zentralbl Gynakol. 1997;119(10):468-75. German. PubMed PMID: 9432825.

245: Kuhn JM, Abourachid H, Brucher P, Doutres JC, Fretin J, Jaupitre A, Jorest R, Lambert D, Petit J, Pin J, Blumberg J, Dufour-Esquerré F. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol. 1997;32(4):397-403. PubMed PMID: 9412795.

246: Gambacciani M, Cappagli B, Piaggesi L, Ciaponi M, Genazzani AR. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int. 1997;61 Suppl 1:S15-8. PubMed PMID: 9263611.

247: Smith JA Jr, Janknegt RA, Abbou CC, de Gery A. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Eur Urol. 1997;31 Suppl 3:25-9. PubMed PMID: 9101212.

248: Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Franssen E, Roche K. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997 Jan;64(1):126-9. PubMed PMID: 8995560.

249: Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. PubMed PMID: 8918410.

250: Akaza H, Isaka S, Usami M, Kanetake H, Kotake T, Koiso K, Aso Y. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Int J Urol. 1996 Nov;3(6):468-71. PubMed PMID: 9170575.

251: Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab. 1996 Nov;81(11):4103-7. PubMed PMID: 8923867.

252: Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996 Nov;48(5):800-4. PubMed PMID: 8911533.

253: Pellicano M, Morgera R, Affinito P, Di Carlo C, Napolitano V, Merlino P, Tremolaterra F, Palomba S, Nappi C. [Effects of ipriflavone on bone loss induced by GnRH analog]. Minerva Ginecol. 1996 Oct;48(10):435-9. Italian. PubMed PMID: 9005368.

254: Elkind-Hirsch KE, Anania C, Malinak R. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression. J Reprod Med. 1996 Sep;41(9):645-52. PubMed PMID: 8887188.

255: Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996 Aug 29;335(9):617-23. PubMed PMID: 8687515.

256: Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996 Aug;14(8):2250-7. PubMed PMID: 8708714.

257: Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996 Jul-Aug;18(4):647-57. PubMed PMID: 8879893.

258: Ruchhoft EA, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril. 1996 Jul;66(1):54-60. PubMed PMID: 8752611.

259: Mukherjee T, Barad D, Turk R, Freeman R. A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am J Obstet Gynecol. 1996 Jul;175(1):105-9. PubMed PMID: 8694034.

260: Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 1996 Jul;81(7):2545-9. PubMed PMID: 8675575.

261: Crosignani PG, Vercellini P, Meschìa M, Oldani S, Bramante T. GnRH agonists before surgery for uterine leiomyomas. A review. J Reprod Med. 1996 Jun;41(6):415-21. Review. PubMed PMID: 8799917.

262: Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Urology. 1996 Jun;47(6):870-7. PubMed PMID: 8677579.

263: Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):22-31. PubMed PMID: 8725888.

264: Ditkoff EC, Sauer MV. A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Hum Reprod. 1996 May;11(5):1035-7. PubMed PMID: 8671386.

265: Sica S, Salutari P, Di Mario A, Chiusolo P, Rutella S, La Barbera EO, Leone G, Scirpa P. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol. 1996 Mar;51(3):248-9. PubMed PMID: 8619413.

266: Marshall LA, Cain DF, Dmowski WP, Chesnut CH 3rd. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol. 1996 Mar;87(3):350-4. PubMed PMID: 8598953.

267: Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson SK, Larson TR, Ferrigni RG. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):535-41. PubMed PMID: 8621275.

268: Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol. 1996;30 Suppl 1:7-14; discussion 19-21. PubMed PMID: 8977984.

269: Marinaccio M, D'Addario V, Serratì A, Pinto V, Cagnazzo G. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol. 1996;17(4):286-8. PubMed PMID: 8856307.

270: Kienle E, Lübben G. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. Urol Int. 1996;56 Suppl 1:23-30. PubMed PMID: 8776814.

271: Fornara P, Jocham D. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma. Urol Int. 1996;56 Suppl 1:18-22. PubMed PMID: 8776813.

272: Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A. Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 1996;56 Suppl 1:13-7. PubMed PMID: 8776812.

273: Tunn UW, Acar O, Goldschmidt AJ. Effects of androgen deprivation prior to radical prostatectomy in 375 patients. Urol Int. 1996;56 Suppl 1:6-12. PubMed PMID: 8776811.

274: Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 Suppl 2:105-9. PubMed PMID: 8717471.

275: Crawford ED. Combined androgen blockade. Eur Urol. 1996;29 Suppl 2:54-61. Review. PubMed PMID: 8717465.

276: Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Urology. 1996 Jan;47(1A Suppl):54-60; discussion 80-4. PubMed PMID: 8560679.

277: Crawford ED. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1995 Dec;46(6):899-901. PubMed PMID: 7502440.

278: Rutgers JL, Spong CY, Sinow R, Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol. 1995 Sep;86(3):386-8. PubMed PMID: 7651647.

279: DeAntoni E, Crawford ED. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. Urologe A. 1995 Sep;34(5):382-8. Review. German. PubMed PMID: 7483154.

280: Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril. 1995 Aug;64(2):313-20. PubMed PMID: 7615109.

281: Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995 Aug;154(2 Pt 1):424-8. PubMed PMID: 7541859.

282: Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995 Jul;86(1):65-71. PubMed PMID: 7784025.

283: Regueiro López JC, Ruiz Alvarez Cienfuegos F, Leva Vallejo M, Requena Tapia MJ, Merchan García JA, Prieto Castro R, Alvarez Kindelan J. [Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade]. Actas Urol Esp. 1995 May;19(5):357-62. Spanish. PubMed PMID: 8659288.

284: Spong CY, Sinow R, Renslo R, Cabus E, Rutgers J, Kletzky OA. Induced hypoestrogenism increases the arterial resistance index of leiomyomata without affecting uterine or carotid arteries. J Assist Reprod Genet. 1995 May;12(5):338-41. PubMed PMID: 8520200.

285: Soloway MS. Role of induction androgen deprivation before radical prostatectomy. Semin Urol. 1995 May;13(2):142-7. Review. PubMed PMID: 7638472.

286: Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995 May;45(5):839-44; discussion 844-5. PubMed PMID: 7538246.

287: Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology. 1995 May;45(5):745-52. PubMed PMID: 7538237.

288: Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer. 1995 Apr 1;75(7):1634-41. PubMed PMID: 8826921.

289: Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 1995 Apr;45(4):633-40. PubMed PMID: 7716844.

290: Taguchi T, Koyama H, Yayoi K, Wada T, Takatsuka Y, Sonoo H, Morimoto K, Tominaga T, Abe R, Enomoto K, et al. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group]. Gan To Kagaku Ryoho. 1995 Mar;22(4):495-508. Japanese. PubMed PMID: 7887641.

291: Taguchi T, Koyama H, Yayoi K, Wada T, Takatsuka Y, Sonoo H, Morimoto K, Tominaga T, Abe R, Enomoto K, et al. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group]. Gan To Kagaku Ryoho. 1995 Mar;22(4):477-94. Japanese. PubMed PMID: 7887640.

292: Watanabe Y, Nakamura G. Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata. Fertil Steril. 1995 Mar;63(3):487-90. PubMed PMID: 7851574.

293: Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 1995;13(1):8-15. PubMed PMID: 7834477.

294: Crawford ED, Hussain M, DeAntoni EP, Thompson IM, Eisenberger MA, Blumenstein B, Coltman CA Jr. Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol. 1995 Jan-Feb;11(1):60-4. Review. PubMed PMID: 7754277.

295: Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 1995;23:149-56. PubMed PMID: 7621455.

296: Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994 Dec;48(6):930-67. Review. PubMed PMID: 7533699.

297: Têtu B. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results. Can J Oncol. 1994 Nov;4 Suppl 1:33-4; discussion 35-6. PubMed PMID: 8853487.

298: Bhasin S, Berman N, Swerdloff RS. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl. 1994 Sep-Oct;15(5):386-91. PubMed PMID: 7860418.

299: Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod. 1994 Sep;9(9):1618-25. PubMed PMID: 7836510.

300: Rivlin ME, Patel RB, Hess LW, Hess DB, Meeks GR. Leuprolide acetate depot for the treatment of uterine leiomyomas. Changes in bone density, uterine volume and uterine vascular resistive index. J Reprod Med. 1994 Sep;39(9):663-6. PubMed PMID: 7807474.

301: Falsetti L, Pasinetti E, Ceruti D. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism. Acta Eur Fertil. 1994 Sep-Oct;25(5):303-6. PubMed PMID: 7660719.

302: Erickson LD, Hartmann LC, Su JQ, Nielsen SN, Pfeifel DM, Goldberg RM, Levitt R, Stanhope CR. Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. Gynecol Oncol. 1994 Aug;54(2):196-200. PubMed PMID: 8063245.

303: Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology. 1994 Jul;44(1):91-5. PubMed PMID: 8042266.

304: Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):755-61. PubMed PMID: 8040021.

305: Stovall TG, Summit RL Jr, Washburn SA, Ling FW. Gonadotropin-releasing hormone agonist use before hysterectomy. Am J Obstet Gynecol. 1994 Jun;170(6):1744-8; discussion 1748-51. PubMed PMID: 8203435.

306: Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol. 1994 Jun;170(6):1623-7; discussion 1627-8. PubMed PMID: 8203418.

307: Kiltz RJ, Rutgers J, Phillips J, Murugesapillai ML, Kletzky OA. Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size. Fertil Steril. 1994 Jun;61(6):1021-6. PubMed PMID: 8194611.

308: D'Anna R, Palmara V, Lo Re C, Scilipoti A, Leonardi I. [Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis]. Minerva Ginecol. 1994 Jun;46(6):343-6. Italian. PubMed PMID: 7936386.

309: Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril. 1994 May;61(5):817-22. PubMed PMID: 8174716.

310: Cohen D, Mazur MT, Jozefczyk MA, Badawy SZ. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy. J Reprod Med. 1994 May;39(5):377-80. PubMed PMID: 7520497.

311: Cirkel U, Ochs H, Roehl A, Schneider HP. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy. Acta Obstet Gynecol Scand. 1994 Apr;73(4):328-32. PubMed PMID: 8160541.

312: Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst. 1994 Mar 16;86(6):431-6. PubMed PMID: 8120917.

313: Morcos RN, Abdul-Malak ME, Shikora E. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil Steril. 1994 Mar;61(3):427-31. PubMed PMID: 8137961.

314: Jiménez Cruz JF, Vera Donoso CD, Iborra I, Solsona E, Forner E, Villavicencio H, Díaz C, González C, Rioja L, Pertusa C, et al. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot]. Actas Urol Esp. 1994 Feb;18(2):90-3. Spanish. PubMed PMID: 7976707.

315: Zaniboni A, Meriggi F, Arcangeli G, Alghisi A, Huscher C, Marini G. Leuprolide and tamoxifen in the treatment of pancreatic cancer. A phase II study. Eur J Cancer. 1994;30A(1):128. PubMed PMID: 8142155.

316: Cheviakoff S, Bocaz JA, Martínez L, Romero C. [Size reduction of uterine myomas with monthly administered leuprolide acetate]. Rev Chil Obstet Ginecol. 1994;59(6):416-20; discussion 420-1. Spanish. PubMed PMID: 7569160.

317: McLeod DG, Benson RC Jr, Eisenberger MA, Crawford ED, Blumenstein BA, Spicer D, Spaulding JT. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3870-3. PubMed PMID: 8252506.

318: Rein MS, Barbieri RL, Welch W, Gleason RE, Caulfield JP, Friedman AJ. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet Gynecol. 1993 Dec;82(6):901-5. PubMed PMID: 8233262.

319: Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med. 1993 Dec;16(6):532-8. PubMed PMID: 8013157.

320: Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med. 1993 Dec;16(6):499-509. PubMed PMID: 8013155.

321: Andros EA, Danesghari F, Crawford ED. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med. 1993 Dec;16(6):510-5. PubMed PMID: 7516835.

322: Adelson MD, Reece MT. Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors. Clin Obstet Gynecol. 1993 Sep;36(3):690-700. Review. PubMed PMID: 8403615.

323: Barbieri RL, Dilena M, Chumas J, Rein MS, Friedman AJ. Leuprolide acetate depot decreases the number of nucleolar organizer regions in uterine leiomyomata. Fertil Steril. 1993 Sep;60(3):569-70. PubMed PMID: 8375543.

324: Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab. 1993 Jun;76(6):1439-45. PubMed PMID: 8501148.

325: Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 1993 May;76(5):1217-23. PubMed PMID: 8496313.

326: Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception. 1993 May;47(5):427-44. PubMed PMID: 8390340.

327: Perino A, Chianchiano N, Petronio M, Cittadini E. Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study. Fertil Steril. 1993 Mar;59(3):507-10. PubMed PMID: 8458448.

328: Benson RC. Total androgen blockade: the United States experience. Eur Urol. 1993;24 Suppl 2:72-6. PubMed PMID: 8262130.

329: Massacesi M, Milkowski M, Gianfranceschi C, Massacesi L. [Short-term therapy of uterine fibromyomatosis with GN-Rh analog]. Minerva Ginecol. 1992 Dec;44(12):641-4. Italian. PubMed PMID: 1491772.

330: Wheeler JM, Knittle JD, Miller JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol. 1992 Nov;167(5):1367-71. PubMed PMID: 1442992.

331: van Haelst-Pisani CM, Richardson RL, Su J, Buckner JC, Hahn RG, Frytak S, Kvols LK, Burch PA. A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer. 1992 Nov 1;70(9):2310-2. PubMed PMID: 1382829.

332: Vitale F, Ruggieri P. LHRH analogues and PCO disease: validity of the use of enantone depot in the treatment of the disease. Acta Eur Fertil. 1992 Nov-Dec;23(6):293-5. PubMed PMID: 1343754.

333: Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril. 1992 Jul;58(1):66-71. PubMed PMID: 1624025.

334: Friedman AJ, Daly M, Juneau-Norcross M, Fine C, Rein MS. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril. 1992 Jul;58(1):205-8. PubMed PMID: 1624009.

335: McLeod DG, Crawford ED, Blumenstein BA, Eisenberger MA, Dorr FA. Controversies in the treatment of metastatic prostate cancer. Cancer. 1992 Jul 1;70(1 Suppl):324-8. PubMed PMID: 1600494.

336: Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1992 Apr;15(2):125-8. PubMed PMID: 1553899.

337: Dawson NA, Wilding G, Weiss RB, McLeod DG, Linehan WM, Frank JA, Jacob JL, Gelmann EP. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer. 1992 Jan 1;69(1):213-8. PubMed PMID: 1727665.

338: Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol. 1992;31(2):167-74. Review. PubMed PMID: 1622631.

339: Dowsett M, Jacobs S, Aherne J, Smith IE. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin Ther. 1992;14 Suppl A:97-103. PubMed PMID: 1606596.

340: Serra GB, Panetta V, Colosimo M, Romanini C, Lafuenti GB, Garcea N, Votano S, Agatensi L. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial. Clin Ther. 1992;14 Suppl A:57-73. PubMed PMID: 1606594.

341: Cirkel U, Ochs H, Schneider HP, Mettler L, Mayer-Eichberger D, Schindler AE, Bühler K, Winkler U, Zahradnik HP, Künzig HJ, et al. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study. Clin Ther. 1992;14 Suppl A:37-50. PubMed PMID: 1606593.

342: Bühler K, Winkler U, Schindler AE. Influence on hormone levels, lipid metabolism and reversibility of endocrinological changes after leuprorelin acetate depot therapy. Clin Ther. 1992;14 Suppl A:104-13. PubMed PMID: 1606590.

343: Gerhard I, Schindler AE, Bühler K, Winkler U, Meinen K, Mancarella D, Hoffmann G, Schüssler B, Kimmig R, Kranzfelder D. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther. 1992;14 Suppl A:3-16. PubMed PMID: 1535021.

344: Crosignani PG, Gastaldi A, Lombardi PL, Montemagno U, Vignali M, Serra GB, Stella C. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther. 1992;14 Suppl A:29-36. PubMed PMID: 1535020.

345: Huben RP. Hormone therapy of prostatic bone metastases. Adv Exp Med Biol. 1992;324:305-16. PubMed PMID: 1492625.

346: Benson RC Jr, Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Dorr FA. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. Semin Oncol. 1991 Oct;18(5 Suppl 6):9-12. PubMed PMID: 1948121.

347: Chime-Udeh E. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2). Conn Med. 1991 Sep;55(9):526-8. Review. PubMed PMID: 1748007.

348: Stovall TG, Ling FW, Henry LC, Woodruff MR. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1420-3; discussion 1423-5. PubMed PMID: 1904681.

349: Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720-5. PubMed PMID: 1901638.

350: Fornara P. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up]. Urologe A. 1991 May;30(3 Suppl):10-2. German. PubMed PMID: 1746070.

351: Aso Y, Kameyama S, Niijima T, Ohmori H, Ohashi T, Murahashi I, Akimoto M, Koiso K, Akaza H, Hosaka M, et al. [Clinical phase III study on TAP-144-SR, an LH-RH agonist depot formulation, in patients with prostatic cancer]. Hinyokika Kiyo. 1991 Mar;37(3):305-20. Japanese. PubMed PMID: 1906239.

352: Crawford ED, Allen JA. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):961-3. PubMed PMID: 2126738.

353: Niijima T, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T, Kawabe K, et al. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR.]. Hinyokika Kiyo. 1990 Nov;36(11):1343-60. Japanese. PubMed PMID: 2126912.

354: Dowsett M, Mehta A, Mansi J, Smith IE. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. Br J Cancer. 1990 Nov;62(5):834-7. PubMed PMID: 2123115; PubMed Central PMCID: PMC1971512.

355: Seltzer VL, Benjamin F. Treatment of pulmonary endometriosis with a long-acting GnRH agonist. Obstet Gynecol. 1990 Nov;76(5 Pt 2):929-31. PubMed PMID: 2120647.

356: Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1114-9. PubMed PMID: 2145765.

357: Sharifi R, Soloway M, Clayton M, Mounzer A, Strub M, Siami P, Lee M. 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate. Anticancer Drugs. 1990 Oct;1(1):29-31. PubMed PMID: 2131032.

358: Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990 Sep 1;66(5 Suppl):1039-44. PubMed PMID: 2118417.

359: Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol. 1990 Sep;76(3 Pt 1):388-94. PubMed PMID: 2116610.

360: Crawford ED, Goodman P, Blumenstein B. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo. Semin Urol. 1990 Aug;8(3):154-8. PubMed PMID: 2119048.

361: Bachus KE, Hughes CL Jr, Haney AF, Dodson WC. The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate. Fertil Steril. 1990 Jul;54(1):27-31. PubMed PMID: 2113488.

362: Goldspiel BR, Kohler DR. Flutamide: an antiandrogen for advanced prostate cancer. DICP. 1990 Jun;24(6):616-23. Review. PubMed PMID: 2193461.

363: Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 1990 Jun;53(6):1018-23. PubMed PMID: 2112489.

364: Rein MS, Friedman AJ, Heffner LJ. Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1990 Jun;70(6):1554-8. PubMed PMID: 2112150.

365: Zawin M, McCarthy S, Scoutt L, Lange R, Lavy G, Vulte J, Comite F. Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging. Radiology. 1990 May;175(2):503-6. PubMed PMID: 2109336.

366: Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab. 1990 Apr;70(4):1096-102. PubMed PMID: 2156885.

367: Fribourg S. Leuprolide depot before myomectomy. Fertil Steril. 1990 Apr;53(4):754. PubMed PMID: 2108064.

368: Friedman AJ, Rein MS, Pandian MR, Barbieri RL. Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo. Fertil Steril. 1990 Feb;53(2):250-3. PubMed PMID: 2105242.

369: Crawford ED. Combination studies with leuprolide. Eur Urol. 1990;18 Suppl 3:30-3. PubMed PMID: 2128828.

370: Akaza H, Aso Y, Koiso K, Fuse H, Isurugi K, Okada K, Usami M, Kotake T, Ohashi T, Ueda T, et al. Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group. J Int Med Res. 1990;18 Suppl 1:90-102. PubMed PMID: 2108889.

371: Bourdin S, Karam G, Clemain P, Bouchot O, Peuvrel P, Lacoste J, Auvigne J. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. J Int Med Res. 1990;18 Suppl 1:74-8. PubMed PMID: 2108888.

372: Navratil H. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer. J Int Med Res. 1990;18 Suppl 1:69-73. PubMed PMID: 2108887.

373: O' Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Int Med Res. 1990;18 Suppl 1:57-68. PubMed PMID: 2108886.

374: Mazzei T, Mini E, Rizzo M, Periti P. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Int Med Res. 1990;18 Suppl 1:42-56. PubMed PMID: 2108885.

375: Nabors W, Crawford ED. Luteinizing hormone releasing hormone agonists: the US experience. J Int Med Res. 1990;18 Suppl 1:31-4. PubMed PMID: 2108884.

376: Rizzo M, Mazzei T, Mini E, Bartoletti R, Periti P. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res. 1990;18 Suppl 1:114-25. PubMed PMID: 2108883.

377: Bischoff W. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group. J Int Med Res. 1990;18 Suppl 1:103-13. PubMed PMID: 2108882.

378: Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol. 1990 Jan;143(1):68-71. PubMed PMID: 2104638.

379: Giraud B. Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer. J Int Med Res. 1990;18 Suppl 1:84-9. PubMed PMID: 1691113.

380: Dodson WC, Hughes CL Jr, Yancy SE, Haney AF. Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. Fertil Steril. 1989 Dec;52(6):915-8. PubMed PMID: 2512181.

381: Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 1989 Dec;74(6):856-62. PubMed PMID: 2511532.

382: Friedman AJ, Rein MS, Harrison-Atlas D, Garfield JM, Doubilet PM. A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril. 1989 Nov;52(5):728-33. Erratum in: Fertil Steril 1990 Oct;54(4):749. PubMed PMID: 2509250.

383: Crawford ED. Combined androgen blockade. Urology. 1989 Oct;34(4 Suppl):22-6; discussion 46-56. Review. PubMed PMID: 2508291.

384: Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420. PubMed PMID: 2503724.

385: Flutamide for prostate cancer. Med Lett Drugs Ther. 1989 Jul 28;31(797):72. PubMed PMID: 2501635.

386: Chodak GW. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. Urology. 1989 May;33(5 Suppl):42-4. Review. PubMed PMID: 2523610.

387: Tummon IS, Pepping ME, Binor Z, Radwanska E, Dmowski WP. A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertil Steril. 1989 Mar;51(3):390-4. PubMed PMID: 2522062.

388: Friedman AJ, Harrison-Atlas D, Barbieri RL, Benacerraf B, Gleason R, Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989 Feb;51(2):251-6. PubMed PMID: 2492232.

389: Kavanagh JJ, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol. 1989 Jan;7(1):115-8. PubMed PMID: 2491882.

390: Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril. 1988 Mar;49(3):404-9. PubMed PMID: 2963759.

391: Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J Steroid Biochem. 1988;30(1-6):107-17. PubMed PMID: 3290578.

392: Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Prog Clin Biol Res. 1988;260:41-62. PubMed PMID: 3283766.

393: Swanson LJ, Seely JH, Garnick MB. Gonadotropin-releasing hormone analogs and prostatic cancer. Crit Rev Oncol Hematol. 1988;8(1):1-26. Review. PubMed PMID: 2964939.

394: Friedman AJ, Barbieri RL, Benacerraf BR, Schiff I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril. 1987 Oct;48(4):560-4. PubMed PMID: 3115833.

395: Garnick MB. Current status of endocrine therapy for prostate cancer. Oncology (Williston Park). 1987 Sep;1(7):19-25, 30-1, 34. Review. PubMed PMID: 3079487.

396: Dodson WC, Hughes CL, Whitesides DB, Haney AF. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 1987 Jul;65(1):95-100. PubMed PMID: 2953752.

397: De la Grange AB. Randomised, double-blind study of estramustine phosphate and leuprolide acetate. Prog Clin Biol Res. 1987;243B:227-8. PubMed PMID: 3116555.

398: Seely JH. Phase III studies in prostatic cancer with leuprolide acetate. J Androl. 1987 Jan-Feb;8(1):S23-6. PubMed PMID: 3104263.

399: Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem. 1986 Nov;25(5B):877-83. PubMed PMID: 3100871.

400: Wojciechowski NJ, Carter CA, Skoutakis VA, Bess DT, Falbe WJ, Mickle TR. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm. 1986 Oct;20(10):746-51. PubMed PMID: 2429815.

401: Eisenberger MA, O'Dwyer PJ, Friedman MA. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol. 1986 Mar;4(3):414-24. Review. PubMed PMID: 2936872.

402: Smith JA Jr. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective. Urology. 1986 Jan;27(1 Suppl):9-15. PubMed PMID: 3079936.

403: Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology. 1986 Jan;27(1 Suppl):21-8. PubMed PMID: 3079935.

404: Leuprolide for prostate cancer. Med Lett Drugs Ther. 1985 Aug 16;27(694):71-2. PubMed PMID: 2410765.

405: Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology. 1985 Aug;26(2):117-24. PubMed PMID: 3927551.

406: Garnick MB, Glode LM, Smith JA Jr, Max DT. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate. Br J Clin Pract. 1985 Feb;39(2):73-6. PubMed PMID: 3921047.

407: Smith JA Jr, Glode LM, Wettlaufer JN, Stein BS, Glass AG, Max DT, Anbar D, Jagst CL, Murphy GP. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology. 1985 Feb;25(2):106-14. PubMed PMID: 3918369.

408: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984 Nov 15;311(20):1281-6. PubMed PMID: 6436700.

409: Winfield H, Trachtenberg J. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J Urol. 1984 Jun;131(6):1107-9. PubMed PMID: 6427477.

410: Elder JS, Catalona WJ. Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin North Am. 1984 May;11(2):283-95. Review. PubMed PMID: 6428022.

411: Warner B, Worgul TJ, Drago J, Demers L, Dufau M, Max D, Santen RJ. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest. 1983 Jun;71(6):1842-53. PubMed PMID: 6408125; PubMed Central PMCID: PMC370390.